MicroRNA as tools and therapeutics in lung cancer

Respiratory Medicine

Volumn 109, Issue 7, 2015, Pages 803-812

  Barger, Jennifer F ^a,b   Nana Sinkam, S Patrick ^a,b,c,d  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Cancer; Lung; microRNA

Indexed keywords

MICRORNA; ONCOPROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; ENZYME INHIBITION; HUMAN; LUNG CANCER; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; LUNG NEOPLASMS; METABOLISM; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROGNOSIS;

EID: 84930756777     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.02.006     Document Type: Review

References (115)

1. National Lung Screening Trial Research Team D.R. Aberle, and A.M. Adams Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med 365 2011 395 409 10.1056/NEJMoa1102873
2. N. Hasan, R. Kumar, and M.S. Kavuru Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers Lung 2014 639 648 10.1007/s00408-014-9636-z
3. S. Cardarella, and B.E. Johnson The impact of genomic changes on treatment of lung cancer Am J Respir Crit Care Med 188 2013 770 775 10.1164/rccm.201305-0843PP
4. R.C. Lee, R.L. Feinbaum, and V. Ambros The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 75 1993 843 854 doi:0092-8674(93)90529-Y [pii]
5. A.E. Pasquinelli, B.J. Reinhart, and F. Slack Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA Nature 408 2000 86 89 10.1038/35040556
6. J. Lu, G. Getz, and E.A. Miska MicroRNA expression profiles classify human cancers Nature 435 2005 834 838 doi:nature03702 [pii]
7. Y. Lee, M. Kim, and J. Han MicroRNA genes are transcribed by RNA polymerase II EMBO J 23 2004 4051 4060 10.1038/sj.emboj.7600385
8. J. Han, Y. Lee, K.H. Yeom, Y.K. Kim, H. Jin, and V.N. Kim The drosha-DGCR8 complex in primary microRNA processing Genes Dev 18 2004 3016 3027 doi:gad.1262504 [pii]
9. X. Cai, C.H. Hagedorn, and B.R. Cullen Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs RNA 10 2004 1957 1966 doi:rna.7135204 [pii]
10. D.A. Hill, J. Ivanovich, and J.R. Priest DICER1 mutations in familial pleuropulmonary blastoma Science 325 2009 965 10.1126/science.1174334
11. Y. Karube, H. Tanaka, and H. Osada Reduced expression of dicer associated with poor prognosis in lung cancer patients Cancer Sci 96 2005 111 115 10.1111/j.1349-7006.2005.00015.x
12. N. Yanaihara, N. Caplen, and E. Bowman Unique microRNA molecular profiles in lung cancer diagnosis and prognosis Cancer Cell 9 2006 189 198 doi:S1535-6108(06)00033-X[pii]
13. S. Volinia, G.A. Calin, and C.G. Liu A microRNA expression signature of human solid tumors defines cancer gene targets Proc Natl Acad Sci U S A 103 2006 2257 2261 doi:0510565103 [pii]
14. P.S. Mitchell, R.K. Parkin, and E.M. Kroh Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci U S A 105 2008 10513 10518 10.1073/pnas.0804549105
15. A. Sittka, and B. Schmeck MicroRNAs in the lung MicroRNA Cancer regulation Vol. 774 2013 121 134
16. S. Gilad, G. Lithwick-Yanai, and I. Barshack Classification of the four main types of lung cancer using a microRNA-based diagnostic assay J Mol Diagn 14 2012 510 517 10.1016/j.jmoldx.2012.03.004
17. J. Takamizawa, H. Konishi, and K. Yanagisawa Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival Cancer Res 64 2004 3753 3756 10.1158/0008-5472.CAN-04-0637
18. J.A. Bishop, H. Benjamin, H. Cholakh, A. Chajut, D.P. Clark, and W.H. Westra Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach Clin Cancer Res 16 2010 610 619 10.1158/1078-0432.CCR-09-2638
19. J. Hamamoto, K. Soejima, and S. Yoda Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma Mol Med Rep 8 2013 456 462 10.3892/mmr.2013.1517
20. D. Lebanony, H. Benjamin, and S. Gilad Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma J Clin Oncol 27 2009 2030 2037 10.1200/JCO.2008.19.4134
21. S. Rosenwald, S. Gilad, and S. Benjamin Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin Mod Pathol 23 2010 814 823 10.1038/modpathol.2010.57
22. I. Barshack, G. Lithwick-Yanai, and A. Afek MicroRNA expression differentiates between primary lung tumors and metastases to the lung Pathol Res Pract 206 2010 578 584 10.1016/j.prp.2010.03.005
23. J. Kim, N.J. Lim, S.G. Jang, H.K. Kim, and G.K. Lee miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal cancer metastases in the lung Anticancer Res 34 2014 2297 2302 doi:34/5/2297 [pii]
24. G. Sozzi, M. Boeri, and M. Rossi Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study J Clin Oncol 32 2014 768 773 10.1200/JCO.2013.50.4357
25. U. Pastorino, M. Rossi, and V. Rosato Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial Eur J Cancer Prev 21 2012 308 315 10.1097/CEJ.0b013e328351e1b6
26. M. Boeri, C. Verri, and D. Conte MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer Proc Natl Acad Sci U S A 108 2011 3713 3718 10.1073/pnas.1100048108
27. J. Shen, Z. Liu, and N.W. Todd Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers BMC Cancer 11 2011 10.1186/1471-2407-11-374 374-2407-11-374
28. T. Winton, R. Livingston, and D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597 doi:352/25/2589 [pii]
29. R.W. Jang, A. Le Maitre, and K. Ding Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the national cancer institute of canada clinical trials group JBR.10 trial J Clin Oncol 27 2009 4268 4273 10.1200/JCO.2008.20.5815
30. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 10.1126/science.1099314
31. L.V. Sequist, R.G. Martins, and D. Spigel First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J Clin Oncol 26 2008 2442 2449 10.1200/JCO.2007.14.8494
32. J.H. Lee, J. Voortman, and A.M. Dingemans MicroRNA expression and clinical outcome of small cell lung cancer PLoS One 6 2011 e21300 10.1371/journal.pone.0021300
33. S.M. Johnson, H. Grosshans, and J. Shingara RAS is regulated by the let-7 microRNA family Cell 120 2005 635 647 doi:S0092-8674(05)00088-7[pii]
34. Y.S. Lee, and A. Dutta The tumor suppressor microRNA let-7 represses the HMGA2 oncogene Genes Dev 21 2007 1025 1030 doi:gad.1540407 [pii]
35. B. Boyerinas, S.M. Park, and A.E. Murmann Let-7 modulates acquired resistance of ovarian cancer to taxanes via IMP-1-mediated stabilization of multidrug resistance 1 Int J Cancer 130 2012 1787 1797 10.1002/ijc.26190
36. C.J. Chang, C.C. Hsu, and C.H. Chang Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer Oncol Rep 26 2011 1003 1010 10.3892/or.2011.1360
37. J.B. Weidhaas, I. Babar, and S.M. Nallur MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy Cancer Res 67 2007 11111 11116 doi:67/23/11111 [pii]
38. Y. Li, T.G. VandenBoom 2nd, and D. Kong Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Cancer Res 69 2009 6704 6712 10.1158/0008-5472.CAN-09-1298
39. G.J. Weiss, L.T. Bemis, and E. Nakajima EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines Ann Oncol 19 2008 1053 1059 10.1093/annonc/mdn006
40. J. Hu, Y. Cheng, and Y. Li microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C Eur J Cancer 50 2014 2336 2350 10.1016/j.ejca.2014.06.005
41. Z.M. Shi, J. Wang, and Z. Yan MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1 PLoS One 7 2012 e32709 10.1371/journal.pone.0032709
42. L.W. Chan, F.F. Wang, and W.C. Cho Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer Curr Top Med Chem 12 2012 920 926 doi:CTMC-EPUB-20120214-010 [pii]
43. S.I. Rothschild, M.P. Tschan, and E.A. Federzoni MicroRNA-29b is involved in the src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma Oncogene 31 2012 4221 4232 10.1038/onc.2011.578
44. D.W. Wu, N.Y. Hsu, and Y.C. Wang C-myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT Oncogene 0 2014 10.1038/onc.2014.152
45. M. Fabbri, R. Garzon, and A. Cimmino MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proc Natl Acad Sci U S A 104 2007 15805 15810 doi:0707628104 [pii]
46. M. Lize, A. Klimke, and M. Dobbelstein MicroRNA-449 in cell fate determination Cell Cycle 10 2011 2874 2882 doi:17181 [pii]
47. N. Bandi, and E. Vassella miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and rb-dependent manner Mol Cancer 10 2011 10.1186/1476-4598-10-55 55-4598-10-55
48. N. Okada, C.P. Lin, and M.C. Ribeiro A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression Genes Dev 28 2014 438 450 10.1101/gad.233585.113
49. L. Kastl, I. Brown, and A.C. Schofield miRNA-34a is associated with docetaxel resistance in human breast cancer cells Breast Cancer Res Treat 131 2012 445 454 10.1007/s10549-011-1424-3
50. J. Zhao, P. Lammers, C.J. Torrance, and A.G. Bader TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.) Mol Ther 21 2013 1678 1686 10.1038/mt.2013.148
51. J.S. Wei, Y.K. Song, and S. Durinck The MYCN oncogene is a direct target of miR-34a Oncogene 27 2008 5204 5213 10.1038/onc.2008.154
52. K. Rai, N. Takigawa, and S. Ito Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells Mol Cancer Ther 10 2011 1720 1727 10.1158/1535-7163.MCT-11-0220
53. K.M. Lee, E.J. Choi, and I.A. Kim microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling Radiother Oncol 101 2011 171 176 10.1016/j.radonc.2011.05.050
54. X.G. Liu, W.Y. Zhu, and Y.Y. Huang High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer Med Oncol 29 2012 618 626 10.1007/s12032-011-9923-y
55. M.J. Schliekelman, D.L. Gibbons, and V.M. Faca Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer Cancer Res 71 2011 7670 7682 10.1158/0008-5472.CAN-11-0964
56. C. Gao, F.H. Peng, and L.K. Peng MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1 Neoplasma 2014 680 689 10.4149/neo-2014-083
57. T.T. Manavalan, Y. Teng, L.M. Litchfield, P. Muluhngwi, N. Al-Rayyan, and C.M. Klinge Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells PLoS One 8 2013 10.1371/journal.pone.0062334 e62334
58. M.A. Cortez, D. Valdecanas, and X. Zhang Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer Mol Ther 22 2014 1494 1503 10.1038/mt.2014.79
59. J. Wei, W. Gao, and C.J. Zhu Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer Chin J Cancer 30 2011 407 414 doi:1944-446X201106407[pii]
60. Y. Shen, D. Tang, and R. Yao microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation Med Oncol 30 2013 10.1007/s12032-013-0750-1 750-013-0750-1. Epub 2013 Nov 6
61. L. Hong, Y. Han, and Y. Zhang MicroRNA-21: a therapeutic target for reversing drug resistance in cancer Expert Opin Ther Targets 17 2013 1073 1080 10.1517/14728222.2013.819853
62. B. Li, S. Ren, and X. Li MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Lung Cancer 83 2014 146 153 10.1016/j.lungcan.2013.11.003
63. M. Garofalo, G. Di Leva, and G. Romano miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation Cancer Cell 16 2009 498 509 10.1016/j.ccr.2009.10.014
64. Z. Mei, Y. He, and J. Feng MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2 FEBS Lett 588 2014 3055 3061 10.1016/j.febslet.2014.06.020
65. X.C. Wang, L.Q. Du, and L.L. Tian Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer Lung Cancer 72 2011 92 99 10.1016/j.lungcan.2010.07.014
66. A. Ruzzo, F. Graziano, and B. Vincenzi High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease Oncologist 17 2012 823 829 10.1634/theoncologist.2012-0081
67. J.B. Kjersem, T. Ikdahl, and T. Guren Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab BMC Cancer 12 2012 10.1186/1471-2407-12-534 534-2407-12-534
68. A. Capodanno, L. Boldrini, and A. Proietti Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features Int J Oncol 43 2013 765 774 10.3892/ijo.2013.2003
69. N. Bandi, S. Zbinden, and M. Gugger miR-15a and miR-16 are implicated in cell cycle regulation in a rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer Cancer Res 69 2009 5553 5559 10.1158/0008-5472.CAN-08-4277
70. E. Gallardo, A. Navarro, and N. Vinolas miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer Carcinogenesis 30 2009 1903 1909 10.1093/carcin/bgp219
71. Z. Wang, Z. Chen, and Y. Gao DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer Cancer Biol Ther 11 2011 490 496 10.4161/cbt.11.5.14550
72. K.Y. Wong, L. Yu, and C.S. Chim DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family Epigenomics 3 2011 83 92 10.2217/epi.10.74
73. N.H. Kim, H.S. Kim, and X.Y. Li A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition J Cell Biol 195 2011 417 433 10.1083/jcb.201103097
74. J. Balca-Silva, S. Sousa Neves, and A.C. Goncalves Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines Anticancer Res 32 2012 1603 1609 doi:32/5/1603 [pii]
75. C. Migliore, A. Petrelli, and E. Ghiso MicroRNAs impair MET-mediated invasive growth Cancer Res 68 2008 10128 10136 10.1158/0008-5472.CAN-08-2148
76. R. Tejero, A. Navarro, and M. Campayo miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma PLoS One 9 2014 e101899 10.1371/journal.pone.0101899
77. M. Yang, H. Shen, and C. Qiu High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer Eur J Cancer 49 2013 604 615 10.1016/j.ejca.2012.09.031
78. M. Jiang, P. Zhang, and G. Hu Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients Mol Cell Biochem 383 2013 67 75 10.1007/s11010-013-1755-y
79. M.T. van Jaarsveld, J. Helleman, and A.W. Boersma miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells Oncogene 32 2013 4284 4293 10.1038/onc.2012.433
80. Y. Imanaka, S. Tsuchiya, F. Sato, Y. Shimada, K. Shimizu, and G. Tsujimoto MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma J Hum Genet 56 2011 270 276 10.1038/jhg.2011.1
81. M. Garofalo, G. Romano, and G. Di Leva EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers Nat Med 18 2011 74 82 10.1038/nm.2577
82. A. Lujambio, S. Ropero, and E. Ballestar Genetic unmasking of an epigenetically silenced microRNA in human cancer cells Cancer Res 67 2007 1424 1429 doi:67/4/1424 [pii]
83. E. Kaminskas, A.T. Farrell, Y.C. Wang, R. Sridhara, and R. Pazdur FDA drug approval summary: Azacitidine (5-azacytidine, vidaza) for injectable suspension Oncologist 10 2005 176 182 doi:10/3/176 [pii]
84. A.G. Bader, D. Brown, and M. Winkler The promise of microRNA replacement therapy Cancer Res 70 2010 7027 7030 10.1158/0008-5472.CAN-10-2010
85. A. Soriano, L. Jubierre, and A. Almazan-Moga microRNAs as pharmacological targets in cancer Pharmacol Res 75 2013 3 14 10.1016/j.phrs.2013.03.006
86. H. Ling, M. Fabbri, and G.A. Calin MicroRNAs and other non-coding RNAs as targets for anticancer drug development Nat Rev Drug Discov 12 2013 847 865 10.1038/nrd4140
87. P. Trang, P.P. Medina, and J.F. Wiggins Regression of murine lung tumors by the let-7 microRNA Oncogene 29 2010 1580 1587 10.1038/onc.2009.445
88. M.S. Kumar, S.J. Erkeland, and R.E. Pester Suppression of non-small cell lung tumor development by the let-7 microRNA family Proc Natl Acad Sci U S A 105 2008 3903 3908 10.1073/pnas.0712321105
89. A. Esquela-Kerscher, P. Trang, and J.F. Wiggins The let-7 microRNA reduces tumor growth in mouse models of lung cancer Cell Cycle 7 2008 759 764 doi:5834 [pii]
90. P. Trang, J.F. Wiggins, and C.L. Daige Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice Mol Ther 19 2011 1116 1122 10.1038/mt.2011.48
91. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy Mol Ther 18 2010 1650 1656 10.1038/mt.2010.136
92. J.F. Wiggins, L. Ruffino, and K. Kelnar Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34 Cancer Res 70 2010 5923 5930 10.1158/0008-5472.CAN-10-0655
93. V.J. Craig, A. Tzankov, M. Flori, C.A. Schmid, A.G. Bader, and A. Muller Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo Leukemia 26 2012 2421 2424 10.1038/leu.2012.110
94. A.G. Bader miR-34-a microRNA replacement therapy is headed to the clinic Front Genet 3 2012 120 10.3389/fgene.2012.00120
95. Mirna Therapeutics Press release: Mirna therapeutics is first to advance MicroRNA into the clinic for cancer 2014 Available at: www.mirnarx.com [accessed August/25]
96. J. Krutzfeldt, N. Rajewsky, and R. Braich Silencing of microRNAs in vivo with 'antagomirs' Nature 438 2005 685 689 doi:nature04303 [pii]
97. K.A. Lennox, and M.A. Behlke Chemical modification and design of anti-miRNA oligonucleotides Gene Ther 18 2011 1111 1120 10.1038/gt.2011.100
98. K.A. Lennox, R. Owczarzy, D.M. Thomas, J.A. Walder, and M.A. Behlke Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier Mol Ther Nucleic Acids 2 2013 e117 10.1038/mtna.2013.46
99. U.A. Orom, S. Kauppinen, and A.H. Lund LNA-modified oligonucleotides mediate specific inhibition of microRNA function Gene 372 2006 137 141 doi:S0378-1119(06)00023-0[pii]
100. M.S. Ebert, J.R. Neilson, and P.A. Sharp MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells Nat Methods 4 2007 721 726 doi:nmeth1079 [pii]
101. L.F. Gebert, M.A. Rebhan, S.E. Crivelli, R. Denzler, M. Stoffel, and J. Hall Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 Nucleic Acids Res 42 2014 609 621 10.1093/nar/gkt852
102. H.L. Janssen, H.W. Reesink, and E.J. Lawitz Treatment of HCV infection by targeting microRNA N Engl J Med 368 2013 1685 1694 10.1056/NEJMoa1209026
103. R.E. Lanford, E.S. Hildebrandt-Eriksen, and A. Petri Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201 10.1126/science.1178178
104. A. Markou, I. Sourvinou, P.A. Vorkas, G.M. Yousef, and E. Lianidou Clinical evaluation of microRNA expression profiling in non small cell lung cancer Lung Cancer 81 2013 388 396 10.1016/j.lungcan.2013.05.007
105. H.H. Cheng, H.S. Yi, and Y. Kim Plasma processing conditions substantially influence circulating microRNA biomarker levels PLoS One 8 2013 e64795 10.1371/journal.pone.0064795
106. K.C. Vickers, B.T. Palmisano, B.M. Shoucri, R.D. Shamburek, and A.T. Remaley MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins Nat Cell Biol 13 2011 423 433 10.1038/ncb2210
107. H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, and J.O. Lotvall Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat Cell Biol 9 2007 654 659 doi:ncb1596 [pii]
108. J.D. Arroyo, J.R. Chevillet, and E.M. Kroh Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma Proc Natl Acad Sci U S A 108 2011 5003 5008 10.1073/pnas.1019055108
109. L. Cheng, R.A. Sharples, B.J. Scicluna, and A.F. Hill Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood J Extracell Vesicles 3 2014 10.3402/jev.v3.23743 10.3402/jev.v3.23743.eCollection 2014
110. J. Skog, T. Wurdinger, and S. van Rijn Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat Cell Biol 10 2008 1470 1476 10.1038/ncb1800
111. G. Rabinowits, C. Gercel-Taylor, J.M. Day, D.D. Taylor, and G.H. Kloecker Exosomal microRNA: a diagnostic marker for lung cancer Clin Lung Cancer 10 2009 42 46 10.3816/CLC.2009.n.006
112. C. Grange, M. Tapparo, and F. Collino Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche Cancer Res 71 2011 5346 5356 10.1158/0008-5472.CAN-11-0241
113. M. Rodriguez, J. Silva, and A. Lopez-Alfonso Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer Genes Chromosom Cancer 53 2014 713 724 10.1002/gcc.22181
114. T. Yamashita, H. Kamada, and S. Kanasaki Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis Pharmazie 68 2013 969 973
115. S. Hao, Z. Ye, and F. Li Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes Exp Oncol 28 2006 126 131 doi:26/514 [pii]